---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281980"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:31:50.622133+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Benitec Q1 net loss $5.1M, cash $16.5M; OPMD NH study screening starts Nov 2022

## Summary
- Net loss of $5.1M ($0.47 loss per share) for fiscal Q1 ended Sep 30, 2022.
- Cash and cash equivalents of $16.5M as of Sep 30, 2022, up from $4.1M at Jun 30.
- OPMD Natural History Study IRB approval received; subject screening begins Nov 2022 at US lead site.
- BB-301 Phase 1b/2a IND/CTA filings planned for Q1 2023; first dosing expected Q2 2023.
- R&D expenses $2.7M, G&A $1.9M for the quarter, both slightly down year-over-year.

## SEC filing metadata
- accession: 0001193125-22-281980
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/0001193125-22-281980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/d412509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281980
- JSON: https://secwatch.observer/filing/0001193125-22-281980.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281980.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported financial results for its fiscal quarter ended September 30, 2022.
  - Period: its fiscal quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/0001193125-22-281980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.